Pages that link to "Q39377399"
Jump to navigation
Jump to search
The following pages link to Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient Database (Q39377399):
Displaying 18 items.
- Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms (Q28222020) (← links)
- Post Hoc Subanalysis of Two Randomized, Controlled Phase 3 Trials Evaluating Diclofenac Potassium for Oral Solution: Impact of Migraine-Associated Nausea and Prior Triptan Use on Efficacy (Q33698292) (← links)
- Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial (Q34164195) (← links)
- The use of triptans in the management of menstrual migraine (Q36305785) (← links)
- Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome (Q36691981) (← links)
- Predictors of Triptan Response in Pediatric Migraine (Q36984540) (← links)
- Migraine, allodynia, and implications for treatment (Q37345140) (← links)
- Improved patient satisfaction and pain evolution with almotriptan in migraine: a primary care study (Q37827498) (← links)
- Sumatriptan succinate : pharmacokinetics of different formulations in clinical practice (Q38046616) (← links)
- Oral triptans and nausea: treatment considerations in migraine (Q38110863) (← links)
- Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study (Q39165515) (← links)
- A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients (Q39543582) (← links)
- Negative predictors of clinical response to triptans in patients with migraine (Q39720265) (← links)
- Large-scale screening and subsequent effects of migraine treatment on the work floor in the Netherlands. (Q46142932) (← links)
- Intercepting migraine: results of early therapy with nonspecific and migraine-specific agents (Q81605185) (← links)
- Pain freedom at 2 hours in migraine after telcagepant 300 mg (Q83416514) (← links)
- Factors associated with insufficient response to acute treatment of migraine in Japan: analysis of real-world data from the Adelphi Migraine Disease Specific Programme (Q97527136) (← links)
- Predicting the response to a triptan in migraine using deep attack phenotyping: A feasibility study (Q99588832) (← links)